BiotechTube
GID Bio

GID Bio

Louisville, United States· Est.
gidbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $23M

Overview

GID Bio is a late-stage private biotech company advancing an autologous Stromal Vascular Fraction (SVF) cell therapy for moderate-to-severe knee osteoarthritis. The company has successfully completed a pivotal Phase 3 FDA IDE clinical trial, demonstrating statistically significant pain reduction and functional improvement versus sham control, with no reported adverse safety events. GID Bio is now preparing a Premarket Approval (PMA) submission to the FDA, positioning it as a potential non-surgical, cell-based therapeutic option for a large and underserved patient population. The leadership team combines deep expertise in regenerative medicine science, medical device development, and commercial healthcare operations.

OrthopedicsOsteoarthritisWound Healing

Technology Platform

Autologous Stromal Vascular Fraction (SVF) cell therapy platform derived from adipose tissue, focusing on a defined cellular population for immunomodulation and tissue repair.

Funding History

2
Total raised:$23M
Series A$20M
Seed$3M

Opportunities

The primary opportunity is addressing the large unmet need in moderate-to-severe knee osteoarthritis, a multi-billion dollar market with limited non-surgical options.
FDA approval would position GID Bio as a first-mover with a personalized, point-of-care cell therapy, potentially delaying or preventing total knee replacements.
The underlying SVF platform could also be expanded to other orthopedic and soft tissue reconstruction indications.

Risk Factors

The company faces significant regulatory risk with its pending PMA submission, as FDA rejection or request for additional data would be a major setback.
Commercial risks include establishing insurance reimbursement for a novel, costly cell therapy and competing against other emerging OA therapies.
Long-term clinical data on durability and safety beyond one year is also untested.

Competitive Landscape

GID Bio competes in the evolving knee OA treatment space, which includes generic pain relievers, corticosteroid/hyaluronic acid injections, late-stage biopharma candidates (e.g., novel analgesics, disease-modifying drugs), and other cell therapy approaches (e.g., allogeneic stem cells, bone marrow aspirate). Its key differentiation is the autologous SVF product and positive Phase 3 sham-controlled data, but it must demonstrate superior value versus established and emerging competitors.

More companies in Cell & Gene Therapy →More companies in United States →